Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Girard

Showing results (41-50 of 113) with videos related to

Pageof 12
Sort By:
JAMA Neurology|July 28, 2020
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisNathaniel Lizak, Charles B Malpas, Sifat Sharmin, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 22, 2015
Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and MonitoringAnthony Traboulsee, Laurent Létourneau-Guillon, Mark Steven Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Science Translational Medicine|January 5, 2022
DICAM promotes T<sub>H</sub>17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammationMarc Charabati, Camille Grasmuck, Soufiane Ghannam, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registrySifat Sharmin, Charles B Malpas, Izanne Roos, et al.
Pageof 12

Showing results (41-50 of 113) with videos related to

Sort By:
Pageof 12
JAMA Neurology|July 28, 2020
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisNathaniel Lizak, Charles B Malpas, Sifat Sharmin, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 22, 2015
Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and MonitoringAnthony Traboulsee, Laurent Létourneau-Guillon, Mark Steven Freedman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Science Translational Medicine|January 5, 2022
DICAM promotes T<sub>H</sub>17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammationMarc Charabati, Camille Grasmuck, Soufiane Ghannam, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2021
Prediction of multiple sclerosis outcomes when switching to ocrelizumabMichael Zhong, Anneke van der Walt, Jim Stankovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registrySifat Sharmin, Charles B Malpas, Izanne Roos, et al.
Pageof 12